ETAP-Lab launches a new in vitro pharmacology activity in the field of proteopathic neurodegenerative diseases ETAP-Lab proudly announces the launch of ETAP-Cell: a new in vitro pharmacology activity in the field of proteopathic neurodegenerative diseases. The creation of this activity has been made possible by the recruitment of Dr Ahmad Allouche (former Head of Biology at SynAging) who is placing his unique expertise in the solubilization and stabilization of oligomeric proteins (AβO, αSO and TauO) at the disposal of ETAP-Lab. As
This year was very exciting for ETAP-Lab and we would like to share with you some of the 2018 major achievements:A new atopic dermatitis model, the DNCB-induced model in Balb/c mice, has been developed with effective studies already in progress.New studies for the account of TEMESIS have been performed showing remarkable effects of their lead TEM1657 drug candidate on Psoriasis and results have been presented in different congresses. Different formulations of their product remaining to be characterized.Jean-François Bisson participated to
ETAP-Lab will be present at the 3rd Annual World Preclinical Congress Europe in Lisbon on November 27-30th. If you are searching for a reliable partner for in vivo preclinical studies, please contact Jean-François BISSON at: firstname.lastname@example.org and you could meet there at the end of November. For more information about the meeting click here.
ETAP-Lab is pleased to announce the upgrade of the ISO 9001 certification, this time based on the latest version of the standard from 2015. Through an internal and external Audit of the OFC (the French Certification Organization): quality assurance, control and monitoring procedures have been carried out to attest to the quality of our services. By being accredited, our company is insuring the customers to meet their expectations by the quality of its management system in the following areas: consulting, advising and expertise of studies
Jean-François Bisson, Head of the Department of Dermatology at ETAP-Lab, was present last week at the 18th Global Dermatology Congress in Budapest, Hungary. Researchers from Europe but also from other non-European countries (USA, India, Jordan, Indonesia…) participated to this congress as well. Therefore, most recent advances have been presented concerning the diagnosis and the treatment of several pathologies including wound healing, psoriasis, atopic dermatitis, acne, facial rejuvenation and skin bleaching. A focus on the use of bioengineered skin for preclinical and clinical
The position: ETAP-Lab invites applications for an exciting young researcher permanent position in research and development of a new models in neurodegenerative disease. The successful candidate will work in a collaborative research environment with academical interactions. The first two years, the candidate will be dedicated to the project BIOPROLOR2*; it is a public-private consortium which aims at discovering new plant-derived molecules with health benefits to speed up the development of innovative drugs and active ingredients. ETAP-Lab leads the strategic axis of
ETAP-Lab (Dr Nicolas Violle, President and CEO) is a well-established CRO, with more than 25 years of market knowledge. ESRP is the offshoot of the highly-recognized INSERM unit “Physiopathology and Imaging of Neurological Disorders” (PhIND; Pr. Denis Vivien, Head of the unit). The new platform STROK@LLIANCE is fully dedicated to preclinical stroke in order to address mechanisms, diagnostics and therapeutics in stroke. STROK@LLIANCE manages projects in the field of stroke for the pharmaceutical industry with high-skilled specialists ensuring expertise and creativity to provide high-level animal studies in a
Publication of a new article written by ETAP-Lab evaluating the effects of green algae on anxiety and depression : “Evaluation of the antidepressant- and anxiolytic-like effects of a hydrophilic extract from the green seaweed Ulva sp. in rats”, Nutr Neurosci. 2017 Jan 19:1-9. PMID:28102110